RU2017135072A - Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого - Google Patents

Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого Download PDF

Info

Publication number
RU2017135072A
RU2017135072A RU2017135072A RU2017135072A RU2017135072A RU 2017135072 A RU2017135072 A RU 2017135072A RU 2017135072 A RU2017135072 A RU 2017135072A RU 2017135072 A RU2017135072 A RU 2017135072A RU 2017135072 A RU2017135072 A RU 2017135072A
Authority
RU
Russia
Prior art keywords
polypeptide
seq
amino acid
acid sequence
tumor
Prior art date
Application number
RU2017135072A
Other languages
English (en)
Russian (ru)
Other versions
RU2017135072A3 (https=
Inventor
Синтия ЛЭНДЕР
Колин БРОФИ
Карин ПЕТЕРСОН
Эндрю ЛУБЕР
Original Assignee
Мори Матрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мори Матрикс, Инк. filed Critical Мори Матрикс, Инк.
Publication of RU2017135072A publication Critical patent/RU2017135072A/ru
Publication of RU2017135072A3 publication Critical patent/RU2017135072A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
RU2017135072A 2015-03-12 2016-03-10 Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого RU2017135072A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562132374P 2015-03-12 2015-03-12
US62/132,374 2015-03-12
PCT/US2016/021843 WO2016145234A2 (en) 2015-03-12 2016-03-10 Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same

Publications (2)

Publication Number Publication Date
RU2017135072A true RU2017135072A (ru) 2019-04-10
RU2017135072A3 RU2017135072A3 (https=) 2019-09-30

Family

ID=56880599

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017135072A RU2017135072A (ru) 2015-03-12 2016-03-10 Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого

Country Status (13)

Country Link
US (1) US9999655B2 (https=)
EP (1) EP3268022A4 (https=)
JP (1) JP2018512401A (https=)
KR (1) KR20170125090A (https=)
CN (1) CN107921082A (https=)
AU (1) AU2016229017A1 (https=)
BR (1) BR112017019343A2 (https=)
CA (1) CA2978941A1 (https=)
HK (1) HK1249433A1 (https=)
MX (1) MX2017011633A (https=)
RU (1) RU2017135072A (https=)
SG (1) SG11201707281QA (https=)
WO (1) WO2016145234A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102827A1 (en) * 2016-12-04 2018-06-07 Expression Pathology, Inc. Improved methods of treating lung cancer by predicting responders to cisplatin-pemetrexed combination therapy
US11408887B2 (en) 2017-05-22 2022-08-09 The National Institute for Biotechnology in the Negev Ltd. Biomarkers for diagnosis of lung cancer
US10952799B2 (en) 2017-05-31 2021-03-23 Covidien Lp Systems and methods for navigational bronchoscopy and selective drug delivery
US20190134153A1 (en) * 2017-06-12 2019-05-09 Moerae Matrix, Inc. Immunomodulatory effect of inhaled kinase inhibitor peptides in lung
CN112334150B (zh) * 2018-06-12 2025-11-18 日内瓦大学 肽蛋白激酶c抑制剂及其用途
US11195062B2 (en) 2018-11-15 2021-12-07 Nantomics, Llc Classification based on characterization analysis methods and systems
EP4004548B1 (en) 2019-07-29 2026-01-14 Yeda Research and Development Co. Ltd Methods of treating and diagnosing lung cancer
CN113261532A (zh) * 2020-02-17 2021-08-17 中山大学 一种肺癌动物模型的构建方法
US20230087078A1 (en) * 2020-03-02 2023-03-23 Washington University Compositions and methods for the treatment of pancreatic cancer
CA3197627A1 (en) * 2020-11-18 2022-05-27 Kimberly SHEPARD Inhalable dry powder formulations comprising angiogenesis inhibitors
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
EP4608401A2 (en) * 2022-10-27 2025-09-03 Bristol-Myers Squibb Company Mk2 inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
AU4115693A (en) 1992-04-24 1993-11-29 Sri International In vivo homologous sequence targeting in eukaryotic cells
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
DE60026982T2 (de) 1999-04-05 2006-11-16 Mannkind Corp., Danbury Verfahren zur bildung von feinem pulver
DK1808438T3 (da) 1999-06-29 2014-10-27 Mannkind Corp Rensning og stabilisering af peptid og proteiner i lægemidler
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
US20060039985A1 (en) * 2004-04-27 2006-02-23 Bennett David B Methotrexate compositions
PL1786784T3 (pl) 2004-08-20 2011-04-29 Mannkind Corp Kataliza syntezy diketopiperazyn
KR101644250B1 (ko) 2004-08-23 2016-07-29 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
BRPI0514410A (pt) 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
IN2015DN00888A (https=) 2006-02-22 2015-07-10 Mannkind Corp
AU2007342674B2 (en) 2007-01-10 2013-09-19 Purdue Research Foundation Polypeptide inhibitors of HSP27 kinase and uses therefor
JP5703466B2 (ja) * 2007-08-07 2015-04-22 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ キナーゼ阻害薬およびその使用
CN102256613B (zh) 2008-10-20 2014-09-10 莫伊莱麦屈克斯公司 用于治疗或者预防粘连的多肽
CA2744104C (en) 2008-12-10 2017-07-18 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
US20130115256A1 (en) 2010-05-24 2013-05-09 Cynthia Lander Methods for treating or preventing vascular graft failure
US10105356B2 (en) * 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9890200B2 (en) * 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
BR112013026313A8 (pt) * 2011-04-12 2018-01-30 Moerae Matrix Inc composições e métodos para prevenir ou tratar doenças, condições ou processos caracterizados por proliferação anormal de fibroblastos e depósito de matriz extracelular
EP3467124A1 (en) * 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
US20140072613A1 (en) 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring

Also Published As

Publication number Publication date
SG11201707281QA (en) 2017-10-30
MX2017011633A (es) 2017-11-02
US9999655B2 (en) 2018-06-19
EP3268022A4 (en) 2018-11-21
US20160263187A1 (en) 2016-09-15
CN107921082A (zh) 2018-04-17
EP3268022A2 (en) 2018-01-17
CA2978941A1 (en) 2016-09-15
HK1249433A1 (zh) 2018-11-02
RU2017135072A3 (https=) 2019-09-30
AU2016229017A1 (en) 2017-09-28
WO2016145234A2 (en) 2016-09-15
WO2016145234A3 (en) 2016-11-03
KR20170125090A (ko) 2017-11-13
JP2018512401A (ja) 2018-05-17
BR112017019343A2 (pt) 2018-05-02

Similar Documents

Publication Publication Date Title
RU2017135072A (ru) Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
JP2018512401A5 (https=)
Socinski et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer
Vaccaro et al. Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Pantziarka et al. Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anti-cancer agents
Spagnolo et al. Upcoming strategies for the treatment of metastatic melanoma
Wang et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
Youngren-Ortiz et al. Development of optimized, inhalable, gemcitabine-loaded gelatin nanocarriers for lung cancer
Zhang et al. Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer
Fulzele et al. Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model
de Jonge et al. Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects
Paudel et al. Targeting lung cancer using advanced drug delivery systems
Shin et al. A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy
Uhm et al. A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma
Kaneko et al. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells
Haghighi et al. Oxaliplatin, 5fluorouracil and leucovorin (FOLFOX4) as first line chemotherapy in elderly patients with advanced gastric cancer
Zhu et al. An elastase nanocomplex with metal cofactors for enhancement of target protein cleavage activity and synergistic antitumor effect
Yu et al. Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis
Kentepozidis et al. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group
US20230065158A1 (en) Oxabicycloheptanes for treatment of small cell lung cancer
Wu et al. A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer
Brus et al. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going?
Ghassami et al. Biodistribution, safety and organ toxicity of docetaxel-loaded in HER-2 aptamer conjugated Ecoflex® nanoparticles in a mouse xenograft model of ovarian cancer
Li et al. Polymeric Micellar Paclitaxel Plus Cisplatin Combined With Tislelizumab as the First‐Line Treatment of Advanced Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
Fujii Recent multidisciplinary approach with molecular targeted drugs for advanced head and neck cancer

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200806